Millipore Acquires BioAnaLab
31st January 2009
Millipore Corporation (NYSE:MIL), a leading provider of technologies, tools and services for the global life science industry, has acquired Isis spin-out BioAnaLab.
Millipore Acquires BioAnaLab
Based in Oxford, BioAnaLab was spun out of the University of Oxford’s Dunn School by Prof Geoff Hale in 2002 to meet the unique requirements of the biopharmaceutical industry. The Oxford University Seed Challenge fund was an early investor.
BioAnalab helps its customers better understand the safety and efficacy of biologic drugs and vaccines by providing a broad range of services to assist with evaluating and advancing these therapeutics from the drug development pipeline to the market. Services offered by BioAnaLab include assay transfer and development, validation & sample analysis, pharmacokinetics and toxicokinetics, immunogenicity, biological potency, and vaccine services.
Millipore acquires BioAnaLab in a move that will bring substantial expertise in biomarker analytical services to strengthen BioAnaLab’s current offering in that area. The transaction also enables Millipore to expand its biopharmaceutical services business into Europe.
